1) Genovese MC, Fleischmann R, Kivitz AJ, et al: Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol, 67:1424-1437, 2015.
2) Smolen JS, Weinblatt ME, Sheng S, et al: a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis, 73:1616-1625, 2014.
3) Weinblatt ME, Mease P, Mysler E, et al: The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ranging Study. Arthritis Rheum, 67:2591-2600, 2015.
4) Genovese MC, Durez P, Richards HB, et al: Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis, 72:863-869, 2013.
5) Pavelka K, Chon Y, Newmark R, et al: A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol, 42:912-919, 2015.